Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Breast Neoplasms × olaparib × Clear all

Phase

Phase 2 26 Phase 1 23 Phase 1/2 8 Phase 3 6 Phase EARLY_PHASE1 2 Phase 4 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Ovarian Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Breast Neoplasms 1

Interventions

Capecitabine 16 Paclitaxel 12 Docetaxel 10 Cyclophosphamide 10 Epirubicin 8 Gemcitabine 7 Letrozole 6 Doxorubicin 6 Carboplatin 6 Trastuzumab 5 Vinorelbine 4 Cisplatin 4 pertuzumab 3 exemestane 3 Neoadjuvant Therapy 3 Drug Therapy 3 Ado-Trastuzumab Emtansine 3 AC protocol 3 130-nm albumin-bound paclitaxel 3 apatinib 2 Zoledronic Acid 2 Thiotepa 2 Taxes 2 Tamoxifen 2 Standard of Care 2 Radiosurgery 2 Melatonin 2 Lapatinib 2 Injections 2 Goserelin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03150576 2022-11-14

PARTNER

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡